Rusconi

Rusconi

Auto-generated profile, based on publicly available information

Rusconi

Division of Haematology Department of Haematology and Oncology Niguarda Cancer Center ASST Grande Ospedale Metropolitano Niguarda Milan Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2019 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
CRChiara Rusconi
Chiara Rusconi
AAAntonella Anastasia
Antonella Anastasia
ACAnnalisa Chiarenza
Annalisa Chiarenza
LMLuigi Marcheselli
Luigi Marcheselli
FCFederica CAVALLO
Federica CAVALLO
O(On Behalf Of Fondazione Italiana Linfomi (Fil)
On Behalf Of Fondazione Italiana Linfomi (Fil)
Summary: Optimal treatment for transformed follicular lymphoma (tFL) is not fully defined. Clinical characteristics and treatments that impact on post‐transformation outcome of 176 biopsy‐proven tFL were analysed. Transformation occurred at initial diagnosis in 52% (Group 1) and after a FL diagnosis in 48% (Group 2). Five‐year overall survival was 84% for Group 1 and 51% for Group 2 (P < 0·001). In Group 1, 5‐year progression‐free survival was superior after rituximab maintenance compared to observation only (94% vs. 53%, P = 0·024). In Group 2, an inverse trend was found between survival and both a higher number of pre‐transformation treatment lines and a short time‐to‐transformation.